The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments.

R. W. Kupka, W. A. Nolen, L. L. Altshuler, K. D. Denicoff, Mark A Frye, G. S. Leverich, P. E. Keck, S. L. McElroy, A. J. Rush, T. Suppes, R. M. Post

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. AIMS: To give a preliminary summary of emerging findings in these areas. METHOD: Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. RESULTS: The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. CONCLUSIONS: The SFBN provides important new data for the understanding and treatment of bipolar disorder.

Original languageEnglish (US)
JournalThe British journal of psychiatry. Supplement
Volume41
StatePublished - 2001
Externally publishedYes

Fingerprint

olanzapine
Antimanic Agents
Demography
National Institute of Mental Health (U.S.)
Excipients
Bipolar Disorder
Antidepressive Agents
Psychiatry
Comorbidity
Randomized Controlled Trials
Biomarkers
Therapeutics
topiramate
gabapentin
lamotrigine

Cite this

The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments. / Kupka, R. W.; Nolen, W. A.; Altshuler, L. L.; Denicoff, K. D.; Frye, Mark A; Leverich, G. S.; Keck, P. E.; McElroy, S. L.; Rush, A. J.; Suppes, T.; Post, R. M.

In: The British journal of psychiatry. Supplement, Vol. 41, 2001.

Research output: Contribution to journalArticle

Kupka, RW, Nolen, WA, Altshuler, LL, Denicoff, KD, Frye, MA, Leverich, GS, Keck, PE, McElroy, SL, Rush, AJ, Suppes, T & Post, RM 2001, 'The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments.', The British journal of psychiatry. Supplement, vol. 41.
Kupka, R. W. ; Nolen, W. A. ; Altshuler, L. L. ; Denicoff, K. D. ; Frye, Mark A ; Leverich, G. S. ; Keck, P. E. ; McElroy, S. L. ; Rush, A. J. ; Suppes, T. ; Post, R. M. / The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments. In: The British journal of psychiatry. Supplement. 2001 ; Vol. 41.
@article{d4f67af4b53a44bcaae515646ef68dfc,
title = "The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments.",
abstract = "BACKGROUND: The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. AIMS: To give a preliminary summary of emerging findings in these areas. METHOD: Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. RESULTS: The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. CONCLUSIONS: The SFBN provides important new data for the understanding and treatment of bipolar disorder.",
author = "Kupka, {R. W.} and Nolen, {W. A.} and Altshuler, {L. L.} and Denicoff, {K. D.} and Frye, {Mark A} and Leverich, {G. S.} and Keck, {P. E.} and McElroy, {S. L.} and Rush, {A. J.} and T. Suppes and Post, {R. M.}",
year = "2001",
language = "English (US)",
volume = "41",
journal = "The British journal of psychiatry. Supplement",
issn = "0960-5371",
publisher = "Royal College of Psychiatrists",

}

TY - JOUR

T1 - The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments.

AU - Kupka, R. W.

AU - Nolen, W. A.

AU - Altshuler, L. L.

AU - Denicoff, K. D.

AU - Frye, Mark A

AU - Leverich, G. S.

AU - Keck, P. E.

AU - McElroy, S. L.

AU - Rush, A. J.

AU - Suppes, T.

AU - Post, R. M.

PY - 2001

Y1 - 2001

N2 - BACKGROUND: The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. AIMS: To give a preliminary summary of emerging findings in these areas. METHOD: Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. RESULTS: The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. CONCLUSIONS: The SFBN provides important new data for the understanding and treatment of bipolar disorder.

AB - BACKGROUND: The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. AIMS: To give a preliminary summary of emerging findings in these areas. METHOD: Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. RESULTS: The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. CONCLUSIONS: The SFBN provides important new data for the understanding and treatment of bipolar disorder.

UR - http://www.scopus.com/inward/record.url?scp=0035378632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035378632&partnerID=8YFLogxK

M3 - Article

C2 - 11450180

VL - 41

JO - The British journal of psychiatry. Supplement

JF - The British journal of psychiatry. Supplement

SN - 0960-5371

ER -